Navigation Links
FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
Date:3/11/2008

our scientists have designed into the compound, yielding a clinically differentiated product in this market."

"This important regulatory milestone enables Arisaph to begin the process of demonstrating the compound's promise in the clinic," commented Alexander "Zan" Fleming, M.D., clinical/regulatory consultant to Arisaph, President and Chief Executive Officer of Kinexum and former head of diabetes review at FDA. "As an endocrinologist, the unprecedented preclinical efficacy of ARI-2243 is very intriguing and the potential benefits for patients are very exciting. I look forward to working with Arisaph to demonstrate the differentiated efficacy and safety of ARI-2243 in the clinic."

As part of the IND submission, Arisaph completed comprehensive nonclinical safety pharmacology and toxicology studies, including 28 day toxicology studies in rats and primates. The results show that ARI-2243 has a favorable safety pharmacology profile and has a high therapeutic index. Based on the preclinical efficacy of ARI-2243, the company believes that low doses will produce superior blood glucose lowering compared with other DPP-4 inhibitors.

Arisaph designed ARI-2243 as a once a day, orally active, smart DPP-4 inhibitor that is highly potent and functionally selective. In vitro, kinetic studies show that ARI-2243 has an extremely high affinity (Ki of 27 picomolar) for the DPP-4 enzyme and drug dissociation from the enzyme is very slow. Such kinetics confer potency and long activity. During OGTT in normal mice, ARI- 2243 was 250 times more potent than sitagliptin and maximally lowered blood glucose by 88%. Additionally, in ZDF rats, an animal model that develops overt diabetes, ARI-2243 significantly reduced hemoglobin A1c (HbA1c) by 2.5% versus no effect with vildagliptin.(3)

In addition to the compelling preclinical efficacy, ARI-2243 is functionally selective through a smart, "soft drug" inactivation process. Specifically, ARI-2243 binds rapidly and tig
'/>"/>

SOURCE Arisaph Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
7. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
11. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- Fortune Oil and Gas, Inc. (OTCPink:FOGC), today announced that ... Inc. with the symbol (OTCPink : FOGCD). FINRA approved ... Also taking effect today is a ten for 1 ... event in the company,s progress according to CEO, ... proceed with the plan and still have any level ...
(Date:9/17/2014)... , Sept. 17, 2014  Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that agreement has been reached ... on the design of a pivotal, Phase 3 ... for the treatment of cutaneous T-cell lymphoma (CTCL).  ...
(Date:9/16/2014)... , 17 settembre 2014 Hologic, Inc. ... il lancio in Europa del Tomcat, un nuovo ... una piattaforma multifunzionale completamente automatizzata, progettata per semplificare ... ed i rischi di errore legati alla gestione ... strumento Tomcat di Hologic riduce il carico di ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 2Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 4Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 5Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 6Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 7Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 2Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 3
(Date:9/17/2014)... 17, 2014 The global metrology services ... due to the key driving factors of increasing demands ... CAGR of 8.2 % puts the metrology services market ... 2018, as stated in a Transparency Market Research report ... Share, Growth, Trends, and Forecast 2012 – 2018”. , ...
(Date:9/17/2014)... This news release is available in Spanish . ... overweight affect more than half of the population in ... organism, one of which affects liver function. Fat accumulates ... circumstances, causes inflammation, fibrosis and finally, cirrhosis. To date, ... been hepatic biopsy. Imaging techniques such as abdominal ecography ...
(Date:9/17/2014)... (GSA) invites all journalists to attend its ... interdisciplinary conference in the field of aging from ... may register free of charge. , An estimated 4,000 ... the Walter E. Washington Convention Center and Marriott Marquis ... From Cells to Societies" and the program schedule contains ...
(Date:9/17/2014)... September 17, 2014 Representatives with Capitol ... sponsor of Thursday’s Anti-Defamation League Event at the Four Seasons ... we consider it an honor to be a sponsor for ... Pain Institute. , Schocket went on to explain that the ... 600 community leaders and members at the Four Seasons to ...
(Date:9/17/2014)... Neon Sport and Fitmark have an ... industry’s most anticipated event, Joe Weider's Olympia Fitness & ... each take home a Neon Sport branded Fitmark Power ... gear. Fitmark will hold entries for the special prize ... , “There’s nothing more exciting than seeing our ...
Breaking Medicine News(10 mins):Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 2Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 3Health News:Magnetic resonance helps to detect and quantify fat in liver 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2
... anti-HLA antibody assays both contribute to characterization ... ... immunosuppression, COLUMBIA, Md., June 1 Data developed by Cylex ... the American Transplantation Congress in Toronto, Canada, suggest,that cell-mediated immunity and ...
... also helped with severe fatigue among patients on chemotherapy ... the more common and unpleasant side effects of treatment ... by the ancient Chinese practice of acupuncture. , A ... and pain and shoulder dysfunction after neck dissection in ...
... treatment of choice for advanced, metastatic prostate cancer has ... testosterone the hormone that fuels prostate-cancer growth ... drugs. While such therapy buys time for patients, it ... resistant to the androgen deprivation and continues to grow. ...
... VA Three new studies published in the June ... focus on what role gender plays in the prognosis ... and the success rates of hearing aid implants in ... the wide variety of critical research being undertaken every ...
... pancreatic, kidney cancers, respectively , , SATURDAY, May ... cancer -- which historically carries a grim prognosis ... cancer drug Gemzar was used after surgery, new ... of pancreatic cancer patients are even candidates for ...
... death for female survivors; cardiovascular events for males ... survived Hodgkin lymphoma as children have an increased risk ... disease as adults, according to a new report. ... -- may help drive these increased risks, according to ...
Cached Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 2Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 3Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 2Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 3Health News:New research offers insight into oral cancer, chronic pediatric ear infections, and hearing health 2Health News:New Hope for Tough-to-Treat Cancers 2Health News:New Hope for Tough-to-Treat Cancers 3Health News:Hodgkin Lymphoma Kids Face Greater Risk of Future Problems 2
... WardWatch has been designed specifically ... medical staff involved in ward rounds. ... medications and dosages, and consultations that ... (Specialist) or Registrar during Ward round ...
... is an advanced medical calculator ... Pediatric Dosing and Critical Care ... a logical complement to other ... the Daviss Drug Guide, PDR ...
... comprehensive guide provides safe, effective, ... information in a quickly accessible ... edition includes the latest drugs ... key nursing implications are highlighted ...
Provides immediate access to comprehensive coverage of more than 325 I.V. drugs, blood products, and solutions....
Medicine Products: